Vanguard Group Inc. Grows Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Vanguard Group Inc. increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,604,512 shares of the biopharmaceutical company’s stock after purchasing an additional 8,032 shares during the quarter. Vanguard Group Inc. owned approximately 9.83% of TG Therapeutics worth $615,286,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its holdings in TG Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company’s stock worth $898,000 after purchasing an additional 8,338 shares during the last quarter. New York State Teachers Retirement System boosted its holdings in TG Therapeutics by 175.0% during the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company’s stock worth $4,746,000 after purchasing an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new position in TG Therapeutics during the first quarter worth about $226,000. GAMMA Investing LLC boosted its stake in TG Therapeutics by 77.7% in the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 1,986 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in TG Therapeutics by 85.4% in the fourth quarter. Wells Fargo & Company MN now owns 331,403 shares of the biopharmaceutical company’s stock valued at $9,975,000 after acquiring an additional 152,682 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a research note on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $46.25.

TG Therapeutics Stock Up 2.8%

TGTX opened at $27.87 on Thursday. The company has a quick ratio of 3.04, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The stock has a market cap of $4.42 billion, a price-to-earnings ratio of 75.32 and a beta of 1.95. TG Therapeutics, Inc. has a twelve month low of $20.39 and a twelve month high of $46.48. The company’s 50-day moving average price is $35.54 and its two-hundred day moving average price is $35.90.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The company had revenue of $141.15 million during the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm’s revenue was up 92.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.04 earnings per share. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Activity at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 10.64% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.